However, compared with anti-PD1 treatment alone, the combination treatment of glimepiride and anti-PD1 showed a weakened therapeutic effect on CT26 tumor inhibition (Figures 4(e)–4(g)). This evidence concerns the gene DDX53 and neoplasm.